search
Back to results

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

Primary Purpose

Kidney Neoplasms, Neoplasm Metastasis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PSC 833
vinblastine
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Kidney Neoplasms focused on measuring Cytochrome P 450, Multi-Drug Resistance, P-Glycoprotein, Pharmacokinetics

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically proven renal cancer with clear cell component: Measurable or evaluable disease; No brain metastases; No grade 2 or greater peripheral neuropathy or neurologic toxicity symptoms. PRIOR/CONCURRENT THERAPY: Biologic Therapy: Not specified. Chemotherapy: No prior or concurrent hypersensitivity to PSC 833 or cyclosporine A. Endocrine Therapy: Not specified. Radiotherapy: No prior radiation therapy within 4 weeks of study. Surgery: No major surgery within 4 weeks of study. Other: No concurrent treatments that interfere with cyclosporine blood concentrations. PATIENT CHARACTERISTICS: Age: 18 and over. Performance Status: ECOG 0-2. Life Expectancy: At least 16 weeks. Hematopoietic: ANC greater than or equal to 1500/mm(3); Platelet count greater than or equal to 100,000/mm(3). Hepatic: Bilirubin no greater than 1.5 x normal; AST no greater than 2.5 x normal. Renal: Creatinine no greater than 2.0 mg/dL OR; Creatinine clearance greater than or equal to 50 mL/min. Cardiovascular: No concurrent angina or myocardial infarction that has not been appropriately treated. Other: Not pregnant or nursing. Effective contraceptive required of all fertile patients. Patients with a history of curatively treated basal cell or squamous cell carcinoma are eligible. No HIV seropositivity. No chronic hepatitis or cirrhosis. Patients with concurrent reversible conditions such as diabetes, hypercalcemia, hyperuricemia, hyperviscosity, infection, renal disease, or spinal cord compression are eligible with appropriate therapy. Patients must give written informed consent.

Sites / Locations

  • National Cancer Institute (NCI)

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 3, 1999
Last Updated
March 3, 2008
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00001570
Brief Title
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Official Title
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
January 2000
Overall Recruitment Status
Completed
Study Start Date
February 1997 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2001 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days. To ensure the safety of a 7 day infusion of PSC 833, one patient is treated for 5 days and a second for 6 days, before the first cohort is enrolled. Vinblastine is administered in escalating doses on days 2-5. At least 3 patients are entered at each dose level. The MTD will be defined as the dose immediately below that at which 2 patients experience dose limiting toxicity. Treatment continues every 28 days.
Detailed Description
The Phase I clinical trial of the combination of 120-hour continuous intravenous infusion of vinblastine with oral PSC 833 has shown activity in patients with advanced malignancies, particularly renal cell cancer. The MTD of vinblastine in combination with the oral drink solution of PSC 833 was determined to be 0.9 mg/m2/day for five days and 12.5 mg/kg po q 12 hours for eight days, respectively. For the soft gel capsule formulation, the MTD was determined to be 0.6 mg/m2/day vinblastine for five days and 4 mg/kg po q 6 hours PSC 833 for eight days. Ataxia was the dose limiting toxicity. Of the 46 patients, two complete remissions and one partial remission were seen among 29 patients with renal cell carcinoma. In this Phase I study, patients with advanced renal carcinoma will be treated with escalating doses of vinblastine given as a 72 hour infusion, starting at approximately 40% of the total standard dose. A shorter infusion schedule of vinblastine was chosen since there is evidence in other cytotoxic combinations that PSC 833 increases the AUC and decreases the plasma clearance of chemotherapeutic agents by approximately twofold. Cytochrome P 450 3A or CYP3A, which is the major cytochrome enzyme in the metabolism of vinblastine and PSC 833, will be measured during the first and fourth cycle through an in vivo test using a single intravenous dose of midazolam, a short-acting benzodiazepine. Vinblastine and PSC 833 pharmacokinetics will be performed at the same time. For patients with accessible lesions, tumor biopsy will be requested.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Neoplasms, Neoplasm Metastasis
Keywords
Cytochrome P 450, Multi-Drug Resistance, P-Glycoprotein, Pharmacokinetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
46 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
PSC 833
Intervention Type
Drug
Intervention Name(s)
vinblastine

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven renal cancer with clear cell component: Measurable or evaluable disease; No brain metastases; No grade 2 or greater peripheral neuropathy or neurologic toxicity symptoms. PRIOR/CONCURRENT THERAPY: Biologic Therapy: Not specified. Chemotherapy: No prior or concurrent hypersensitivity to PSC 833 or cyclosporine A. Endocrine Therapy: Not specified. Radiotherapy: No prior radiation therapy within 4 weeks of study. Surgery: No major surgery within 4 weeks of study. Other: No concurrent treatments that interfere with cyclosporine blood concentrations. PATIENT CHARACTERISTICS: Age: 18 and over. Performance Status: ECOG 0-2. Life Expectancy: At least 16 weeks. Hematopoietic: ANC greater than or equal to 1500/mm(3); Platelet count greater than or equal to 100,000/mm(3). Hepatic: Bilirubin no greater than 1.5 x normal; AST no greater than 2.5 x normal. Renal: Creatinine no greater than 2.0 mg/dL OR; Creatinine clearance greater than or equal to 50 mL/min. Cardiovascular: No concurrent angina or myocardial infarction that has not been appropriately treated. Other: Not pregnant or nursing. Effective contraceptive required of all fertile patients. Patients with a history of curatively treated basal cell or squamous cell carcinoma are eligible. No HIV seropositivity. No chronic hepatitis or cirrhosis. Patients with concurrent reversible conditions such as diabetes, hypercalcemia, hyperuricemia, hyperviscosity, infection, renal disease, or spinal cord compression are eligible with appropriate therapy. Patients must give written informed consent.
Facility Information:
Facility Name
National Cancer Institute (NCI)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
7855615
Citation
Chapman AE, Goldstein LJ. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol. 1995 Feb;22(1):17-28. No abstract available.
Results Reference
background
PubMed Identifier
8636778
Citation
Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996 Feb;14(2):610-8. doi: 10.1200/JCO.1996.14.2.610.
Results Reference
background
PubMed Identifier
1359150
Citation
Twentyman PR. MDR1 (P-glycoprotein) gene expression--implications for resistance modifier trials. J Natl Cancer Inst. 1992 Oct 7;84(19):1458-60. doi: 10.1093/jnci/84.19.1458. No abstract available.
Results Reference
background

Learn more about this trial

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

We'll reach out to this number within 24 hrs